High definition analyses of single cohort, whole genome sequencing data provides a direct route to defining sub-phenotypes and personalising medicine

Joyce KE^{1,2}, Onabanjo E³, Brownlow S³, Nur F³, Olupona KO³, Fakayode K³, Sroya M⁴, Thomas G⁴, Ferguson T³, Redhead J³, Millar CM^{3,5}, Cooper N^{3,5}, Layton DM^{3,5}, Boardman-Pretty F⁶, Caulfield MJ^{6,7}, Genomics England Research Consortium⁶, Shovlin CL^{2,3,8*}

¹Imperial College School of Medicine, Imperial College, London UK; ²Genomics England Respiratory Clinical Interpretation Partnership (GeCIP); ³West London Genomic Medicine Centre, Imperial College Healthcare NHS Trust, London UK; ⁴Department of Surgery and Cancer, Imperial College London, UK; ⁵Centre for Haematology, Department of Immunology and Inflammation, Imperial College London UK; ⁶Genomics England, UK; ⁷William Harvey Research Institute, Queen Mary University of London, London UK; ⁸National Heart and Lung Institute, Imperial College London UK.

Word Count 4778

Abstract 150

Figures – 5

Data Supplement File- 1

***Corresponding Author:** Claire L. Shovlin PhD FRCP, National Heart and Lung Institute, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. Email c.shovlin@imperial.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

JOYCE KE, ONABANJO E, BROWNLOW S, NUR F, OLUPONA K, FAKAYODE K, SROYA M, THOMAS G, FERGUSON T, REDHEAD J, MILLAR CM, COOPER N, LAYTON DM, BOARDMAN-PRETTY F, CAULFIELD MJ, GENOMICS ENGLAND RESEARCH CONSORTIUM, SHOVLIN CL. HIGH DEFINITION ANALYSES OF SINGLE COHORT, WHOLE GENOME SEQUENCING DATA PROVIDES A DIRECT ROUTE TO DEFINING SUB-PHENOTYPES AND PERSONALISING MEDICINE. *UPLOADED 28.08.2021, VERSION 1 MEDRXIV/2021/262560*

ABSTRACT

Possession of a clinical or molecular disease label alters the context in which life-course events operate, but rarely explains the phenotypic variability observed by clinicians. Whole genome sequencing of unselected endothelial vasculopathy patients demonstrated more than a third had rare, likely deleterious variants in clinically-relevant genes unrelated to their vasculopathy (1 in 10 within platelet genes; 1 in 8 within coagulation genes; and 1 in 4 within erythrocyte hemolytic genes). High erythrocyte membrane variant rates paralleled genomic damage and prevalence indices in the general population. In blinded analyses, patients with greater hemorrhagic severity that had been attributed solely to their vasculopathy had more deleterious variants in platelet (Spearman $\rho=0.25$, $p=0.008$) and coagulation (Spearman $\rho=0.21$, $p=0.024$) genes. We conclude that rare diseases can provide insights for medicine beyond their primary pathophysiology, and propose a framework based on rare variants to inform interpretative approaches to accelerate clinical impact from whole genome sequencing.

INTRODUCTION

High definition medicine offers opportunities to advance clinical care from single disease-based approaches, where trials of thousands of individuals are used to identify best practice, to a tailored approach for each patient encompassing multi-morbidities and health enhancers. Personalising medicine is anticipated not only to enhance efficacy and efficiency of interventions, but also to reduce adverse events from unnecessary investigations or treatments.

Sequencing the whole genome provides one potential blueprint for such personalisation, though the challenges required for full potential to be realised cannot be over-estimated.[1] Furthermore, delivering numeric and clinical-level confidence to guide personalised medicine is demanding in the setting of individually unique genomes. We hypothesised that some challenges could be overcome in a generally instructive manner by applying whole genome sequencing to a set of well characterised endothelial vasculopathies where the abnormal vascular structures may unmask deleterious potential of variants in disease-independent genes that would usually result in subclinical hematological phenotypes.

The most common of the endothelial vasculopathies, hereditary hemorrhagic telangiectasia (HHT), has established clinical diagnostic criteria, known causal genes, and expert consensus informing clinical practice across general and sub-speciality management.[2-4] Estimated to affect approximately 1.5 million individuals worldwide,[5,6] HHT usually results from a heterozygous loss-of-function allele in *ENG*, *ACVRL1* or *SMAD4*, and is inherited as an autosomal dominant trait.[7] Haploinsufficiency at one of these loci predisposes to the development of abnormal vascular structures, especially arteriovenous malformations (AVMs) characterised by turbulent flow and defective vascular walls predisposing to hemorrhage.[8] Affected individuals experience spontaneous, recurrent nosebleeds due to abnormal nasal vasculature, and exhibit small visible telangiectatic vessels that tend to develop on the lips, oral cavity, and finger pads.[3,4] Many have long-term excellent health with modest hemorrhagic losses, though most experience nosebleeds sufficient to lead to iron deficiency anemia unless dietary iron intake is supplemented,[9] and significant proportions require surgical interventional treatments, and/or disease modifying drugs such as anti-angiogenic agents.[2,3,10] Patients are

commonly found to have silent visceral AVMs, where screening/primary prevention strategies have led to improved life expectancy.[11,12]

As is typical in medicine, it remains impossible to predict which patients will develop complications prior to, and/or despite preventative treatments. Marked diversity in vascular malformations between affected members of the same family were emphasised in the earliest genetic studies,[13] but more strikingly, similar vascular abnormalities can have profoundly different impacts: HHT hemorrhagic severity varies both in severity of recurrent bleeds from nasal or gastrointestinal telangiectasia,[2-4] and rare but life-threatening acute hemorrhages from pulmonary or cerebral AVMs.[14,15] Inflammation is not a prominent feature of HHT,[9] and the limited available data suggest iron handling is appropriate,[9] but in one study, anemia was out-of-proportion to hemorrhagic iron losses in more than a quarter of consecutive hospital-reviewed patients, with evidence for reduced red blood cell (erythrocyte) survival in nearly half of these.[16] Counterintuitively, age-adjusted incidence rates of venous thromboembolism (VTE) are several-fold higher in HHT than in the general population,[17,18] while HHT-affected individuals who have VTE are more likely to have a major deep-seated infection that is a particular risk when venous blood can evade pulmonary capillary processing by passage through right-to-left shunts provided by pulmonary AVMs.[19-22] Socio-environmental exposures can aggravate HHT, as detailed elsewhere,[3,16,17,20,23-30] but only a proportion of patients with these added “risk factors” develop the respective clinical phenotypes. There are hints of familial predispositions [16,17,20,23,24,27] supported by case series where occasional individuals had coincidental non-HHT genetic contributors to their complications.[16,17]

Here we report the magnitude of deleterious genomic variability across clinically-relevant genes, categorised to enhance statistical power, in an essentially unselected cohort of vasculopathy patients who had undergone whole genome sequencing through the National Health Service’s 100,000 Genomes Project.

RESULTS

Patient cohort demographics

104 individuals were recruited with HHT from a single Genomic Medicine Centre. They were from 89 families. At the time of recruitment, patient ages ranged from 17-87 years (median 50 years), and 66 (64%) were female. 56/89 (63%) of families were found to have heterozygous variants in one of the 6 genes currently on HHT (endothelial vasculopathy) gene testing panels in the UK National Health Service, namely *ENG*, *ACVRL1*, *SMAD4*, *GDF2*, *RASA1*, and *EPHB4* (*Figure 1A*). In keeping with the “HHT gene negative” status of a proportion of families on recruitment, in 33/89 (37%) of families, no variants were identified in known HHT genes.

Gene-level variation

A total of 105 variants were identified within the cohort in the 75 selected hematological genes (*Supplementary Table 1*). At least one variant was present in 52/104 (50%) of the study cohort, and 56/75 (75%) of genes had at least one variant identified in the study cohort.

The variant burden was not specific to the study cohort, as the gene damage index (GDI [31]) was also greater in the genes harboring variants in the study cohort (*Figure 1Bi*), providing evidence that these genes are more damaged in the general population. There was no difference between the variant and non-variant genes for residual variation intolerance (RVIS, *Figure 1Bii*), a measure of genic intolerance that performs better for detecting causality for recognised diseases.[32]

The variants were identified in all five categories of hematological genes, i.e. in the major categories of congenital hemolytic anemias (hemoglobin, erythrocyte membrane and erythrocyte enzyme production),[33] together with coagulation and platelet genes relevant to hemorrhagic and thrombotic states [34] (*Figure 1Ci*). Variants were over-represented in the red cell membrane production category although the excess was less pronounced for variants predicted to be more deleterious (*Figure 1Ci*). It was noted that population-wide differences between the five categories of genes primarily reflected lower gene damage indices in the enzymopathy and hemoglobin categories (*Figure 1D*).

Figure 1: Gene-level metrics. **A)** Endothelial vasculopathy genes and variants identified in current study cohort. Note the major HHT genes are *ENG* and *ACVRL1*, [7] while *EPHB4* and *RASA1* cause separate endothelial vasculopathies (CM-AVM2 and CM-AVM1) which overlap phenotypically with HHT. **B)** Population-level burden of genetic damage in the 6 endothelial vasculopathy genes (blue), and 75 study hematological genes (red), as detailed in *Supplementary Table 1*. The study genes were sub-categorised by variant presence ('variant genes', N=56) and absence ('no-variant genes', N=19) in the study cohort. **Bi)** Gene damage index (GDI) Phred scores. [31] **Bii)** Residual variation intolerance scores (RVIS). [32] **C)** The five process-level categories: Respective category contributions in the study cohort are shown for the total number of genes, variants, and variants with Combined Annotation Depletion (CADD [35-37]) score >15 (likely deleterious, as described further in text): Each box represents the percentage for the row, as indicated by the heat scale. **D)** Variation burden within the general population for the 75 study genes in the respective categories: **Di)** Gene damage index (GDI) Phred scores [31], and **Dii)** Residual variation intolerance scores (RVIS). [32] All box plots indicate median and interquartile range, error bars full range. Overall p-values were calculated by Kruskal Wallis with Dunn's multiple comparison test used to derive p-values for pre-selected pair-wise comparisons indicated by arrows.

Variants were identified in genes on all chromosomes except Chr21 and ChrY (*Figure 2Ai*). The number of variants per Mb of selected gene loci varied in accordance with locus positions for genes with high GDI and RVIS scores (*Figure 2Ai*). Variant-containing genes were also distributed throughout the genome for patients with variants in the HHT genes *ACVRL1* and *ENG* (*Figure 2Aii*). All variants were rare in the general population, with GnomAD 3.1.1 [38] allele frequencies less than 0.3%, median GnomAD allele frequency less than 0.05% for each of the five categories, and no significant differences between the 5 categories of genes (Kruskal Wallis $p=0.53$, *Figure 2B*).

Variant deleteriousness

Variant CADD scores ranged from 1-42 (median 15), with the distribution differing between categories ($p=0.0073$, *Figure 2C*). Fifty-seven of 105 variants (54.3%) had CADD scores greater than 15, and at least one variant with a CADD score >15 was present in 38/104 (36.5%) of the study cohort.

Variants in the hemoglobin and red cell membrane production categories were more likely to have lower CADD scores than variants in enzyme, coagulation and platelet genes where more than 75% of CADD scores exceeded 15 (Kruskal Wallis $p=0.0073$, *Figure 2C*). Across all genes with variants, the CADD score delimiter of 15 captured the median 90% mutation significance cutoff (MSC) threshold (*Figure 2D*), while the CADD score delimiter of 5 captured the 90% MSC threshold of all except one gene (*Figure 2D*). In view of these findings, the simple categories of CADD score <5 (likely benign), 5-15 (uncertain significance) and >15 (likely deleterious) were retained generally for the purposes of the manuscript, but two CADD <15 variants in the outlying gene *SPTA1*, were tested in both uncertain significance and deleterious categories.

Figure 2: Variant-level metrics. **A)** Genome positions of the 56 variant-containing genes in the study cohort. **Ai)** Chromosomal distributions of variant-containing genes per 100Mb of DNA (grey circles/lines), number of variants per Mb (red shaded background), and variants with CADD score >15 (red circles/lines), per Mb of gDNA by chromosome [39]. **Aii)** Genome ideogram [40,41] indicating positions of the 56 study genes with variants (red), and the two major HHT genes *ACVRL1* and *ENG* (grey). Variants identified in patients with an identified variant in HHT genes are indicated for *ACVRL1* (purple lines) and *ENG* (blue lines). To preserve anonymity, data for the single *SMAD4*, *GDF2* and *EPHB4* families are not illustrated. **B)** Allele frequencies in GnomAD 3.1.1,[38] and **C)** CADD scores [35-37] of all variants by category. Box plots indicate median and interquartile range, error bars 95% confidence intervals, with dots indicating outliers, horizontal line indicating CADD score of 15, and p-values calculated by Kruskal Wallis. **D)** Gene-level mutation significance cutoff (MSC) scores[42], indicating the lower limit of the 90th and 95% confidence intervals for deleterious CADD scores in individual genes (grey violin plots) compared to the CADD score distribution of variants identified in the study cohort (red). Vertical dotted lines represent overall CADD scores 5 and 15, and the violin plot median and interquartile ranges. **E)** Number of variants in the 75 study genes by category, within the GnomAD 3.1 dataset (grey), and current cohort (red), plotted as number per 100 genomes. Lower graph, rate of any variants/100 genomes compared to the number/100genomes of likely pathogenic and loss of function variants in the same genes in GnomAD 3.1 dataset. Upper graph, rate of deleterious variants/100 genomes compared between the two cohorts- study cohort genes CADD score >15, GnomAD 3.1 as defined in Methods section.

Variant enrichment metrics

Gene damage indices and genic intolerance scores had suggested that there may be enrichment of variants in several categories within the study cohort (*Figure 1*). This was observed in the general population captured in GnomAD 3.1,[38] which, as in the study population, also contained a greater proportion of variants in red cell membrane genes (*Figure 2D*, lower panel).

A different pattern emerged for deleterious variants. All gene categories displayed at least 7.2-times more deleterious variants in the study cohort compared to GnomAD 3.1, per 100 genomes, in part reflecting the more liberal CADD score method to assign deleterious variants. However, enrichment varied between the categories, with a mean enrichment of 26-fold, and maximum 64-fold enrichment (*Figure 2D*, upper panel). By two-way ANOVA across all 75 genes, the 5 categories only accounted for 2.5% of the total variance ($p=0.35$), compared to 19.9% from the cohorts ($p<0.0001$). However, restricting to the 30 genes where deleterious variants were defined in both cohorts, while all variants were only enriched 1.2-2.4 fold (Kruskal Wallis $p=0.63$), deleterious variants were enriched 38.4 to 385-fold (Kruskal Wallis $p=0.039$).

Patient subcategory classifications

To examine if presence or enrichment of deleterious variants may be biologically relevant in the study cohort, the variants were examined in the context of patient phenotypes. Blinded to the variants identified in hematological genes, the recruited patients had been assigned to relevant scales for more extreme phenotypes (*Figure 3A*). Notably, in this group of patients ‘selected’ purely due to the absence of a known family HHT genotype and attendance at the UK reference centre during recruitment to the 100,000 Genomes Project, 36/104 (35%) were categorised with severe hemorrhage, 29/104 (28%) with disproportionate anemia, and 8 (8%) had venous thromboembolic disease. Deep-seated infections affected 13/104 (13%): 10 were in association with concurrent and presumed causative pulmonary AVMs (cerebral and spinal abscesses, spinal discitis, and septic arthritis, due to polymicrobial flora, particularly anaerobic and aerobic commensals of the gastrointestinal and periodontal spaces, as described [19-21]).

Quantitative phenotypic traits

Quantitative traits differed between patients (*Figure 3B*). For each of the five categories of genes, the distribution of quantitative traits was compared between patients with no variants or CADD <5 variants (“likely benign”); CADD 5-15 variants (“uncertain significance”), and CADD >15 variants (“likely deleterious”, *Figure 3C*).

Figure 3: HHT patient subcategories and variation. **A)** Schematic of cohort of 104 plotted on 4 separate axes for hemorrhage [H], anemia [A], thrombosis [T], and deep seated infection [I]. Blue numbers indicate the number of the cohort with no events/no excess (H_0 , A_0 , T_0 and I_0), precipitated events (H_1 , A_1 , T_1), and spontaneous events (H_2 , A_2 , T_2 and I_1). I_1 were cerebral abscess (N=6), spinal discitis (N=2), spinal abscess (N=1), septic arthritis (N=1), recurrent bacterial endocarditis (N=1), osteomyelitis (N=1), and recurrent sepsis (N=1). **B)** Two-way distribution plots of all captured same-day measurements of hemoglobin, mean corpuscular volume (MCV), platelet counts, mean platelet volume (MPV), haematocrit, fibrinogen, and activated partial thromboplastin (APTT), with normal ranges indicated for MCV, MPV, platelet count, and fibrinogen. **C)** Quantitative phenotypic measurements categorised by presence, absence and CADD score of variants in i/ii) hemoglobin genes; iii/iv) red cell membrane genes; v/vi) red cell enzyme genes; vii/viii) coagulation genes; ix/x) platelet genes. Data points represent all datasets captured in the 104 patients across their clinical assessments. Two indices are shown per category, but there were no differences observed between categories for other erythrocyte indices (data not shown).

For hemoglobin (*Figure 3Ci,ii*), red cell membrane (*Figure 3Ciii,iv*), and red cell enzyme (*Figure 3Cv,vi*) genes, there was no discernible difference in any measured red cell index by the presence of variants, with the median of each category within the respective normal range. Similarly, for coagulation genes, there was no discernible difference in prothrombin time or activated partial thromboplastin (APTT) time according to the presence of a variant (*Figure 3Cvii, viii*). The only category where a median value lay outside of the normal range was for platelet gene variants: platelet counts were higher for individuals who had variants with CADD scores between 5-15 (*Figure 3Cix*). Mean platelet volume did not differ where measured in the 3 of these (*Figure 3Cx*), and similar platelet count trends were not observed for the higher impact variants (*Figure 3Cix*). We concluded that the variants were not clearly reflected in variability within patient quantitative traits at specifically sampled times.

Phenotypic categories

Next we examined gene variants across the categories by clinical phenotypes over the patients' life-times to date. We restricted analyses to the presence of variants where CADD scores were >15, i.e. the 'likely deleterious' variant group. Variants with CADD scores >15 were present in all severe hemorrhage, disproportionate anemia, spontaneous thrombosis and severe deep-seated infection categories, but notably were also present in each of the 4 "no event" categories (*Figure 4A*).

Hemoglobin gene variants with CADD scores >15 tended to distribute towards the "no event" categories (*Figure 4A*, lower left pie charts). Examining by binary categories that pooled precipitated and spontaneous events, deleterious hemoglobin gene variants were not enriched in any of the 4 phenotypic severity categories (*Figure 4B*).

Visual inspection suggested that erythrocyte membrane gene variants might be enriched in the 11 patients with severe deep-seated infections (*Figure 4A lower middle pie charts, Figure 5B*). There was no material difference denoting the *SPTA1* variants with CADD scores of 12.73 and 13.38 as deleterious

A

B

Figure 4: Burden of deleterious variants by categories of genes and phenotypic severity profiles. **A)** The burden of deleterious (CADD >15) variants in the 5 categories of genes for each pre-defined phenotypic subcohort. Filled pie-chart regions quantify the number of CADD>15 variants per patient in the category (grey if pooling across all gene categories, red if gene category-specific, fully filled if one variant per patient). The 10 variants with CADD scores of 1-5 (“likely benign”), and 36 with CADD scores between 5 and 15 (“of uncertain significance”) are effectively included in the remaining white pie chart regions, to enhance clarity. For each set of 6 pie charts, gene category placements are consistent. The upper row indicates total number of CADD>15 variants across all categories, and the remaining upper row pie charts focus on hemorrhage (upper middle for coagulation genes, upper right for platelet genes). The lower row presents the red cell gene categories (lower left for hemoglobin genes, lower middle for erythrocyte (red cell) membrane genes, and lower right for erythrocyte enzyme genes). The set of 6 grey-lined empty pie charts indicate there were no patients in the pre-defined A1 category. **B)** Heat maps for number of variants per patient in each phenotypic subcohort, where the precipitated and spontaneous H1/H2, T1/T2, and A1/A2 subcohorts have been pooled. Trends highlighted in the text are denoted by a grey cross, or black star where * indicates p<0.05, and *** p<0.01. The gene where MSC CADD score adjustments were made (*SPTA1*) was in the membrane category, and adjustment by MSC CADD did not materially alter these findings.

(tested because *SPTAI* was an outlier gene with a 90% CADD MSC of 0.7), since one individual already had another variant in the category with a CADD score >15, and the second individual did not have a deep-seated infection. Similarly, visual inspection suggested that erythrocyte enzyme variants might be enriched in the 6 patients with unprovoked venous thromboemboli (*Figure 4A lower right pie charts, Figure 5B*). However, these were based on small numbers, and unsuited to statistical examination.

The hemorrhage and thrombosis phenotypes provided greater statistical power, since, as indicated in *Figure 3*, these can be considered to represent opposing ends of a spectrum. There were trends for deleterious variants in both coagulation genes (*Figure 4A upper middle pie charts*), and platelet genes (*Figure 4A upper right pie charts*) to be distributed towards the more severe hemorrhagic categories. Examining three-point scales of severe hemorrhage - usual hemorrhage – thrombosis, using non parametric Spearman's correlations, deleterious (CADD>15) variants were enriched in patients with more severe hemorrhage, for both platelet ($\rho = 0.25$, $p=0.008$), and coagulation ($\rho = 0.21$, $p=0.024$) gene categories (*Figure 4B*).

DISCUSSION

We have shown for 75 hematological genes where variants can cause heritable human disease, that deleterious variants are commonly found in man. Despite each variant individually being rare (allele frequency < 0.3%), overall more than a third of patients with an inherited vasculopathy that places them at risk of hemorrhage and anemia had at least one likely deleterious variant in diverse genes that could augment or modify these disease complications. In particular, patients with more severe hemorrhage that had been attributed solely to their diagnosed condition had a higher number of rare, deleterious variants in unrelated platelet and coagulation genes located across the genome. These findings provide evidence that even modestly-sized rare disease cohorts provide a framework for accelerating delivery of informed clinical care through whole genome sequencing using interpretative approaches based on phenotype-based targeting of genes with established pathogenic potential.

Most attention on the potential of DNA sequencing to personalise medicine focuses on discovery of novel genetic causes of disease,[1,43] and development of polygenic risk scores from large-scale studies identifying common variation across blocks of genes co-inherited in linkage disequilibrium[44] that can direct attention to novel *cis*-regulatory elements.[44,45] The presented approach offers an accelerated route to the clinic, by proceeding from genes already known to have functional impact in processes potentially relevant to the patient. While a small proportion of rare deleterious variants cause recognised human diseases, most do not, either because they are not present at sufficient zygosity, or because they are not in an appropriate patient/environment milieu to be exposed above an essentially compensated perturbation to normal physiology. Major databases emphasise the very high rates of rare deleterious variants in the human general population.[38] The current study offers an indicative example of how aberrant physiology imposed by an endothelial vasculopathy appears to augment the impact of variants in separate systems that might otherwise be clinically insignificant. More generally, the approach can be adopted in a framework of personalised genomic interpretations (PGIs) either in ‘towards PGI’ studies as in the current manuscript to provide statistical support, or ‘for PGI’ studies to deliver what is genuinely personalised, N=1 medicine (*Figure 5*).

Figure 5. Framework for studies ‘towards personalised genomic interpretations’ (TPGI). The ‘MALO’ phenotypic severity scale refers to **M**ore severe than expected for disease; **A**s expected for disease; **L**ess severe than expected for disease, and (if feasible) **O**pposite phenotype. WGS, whole genome sequencing; WES, whole exome sequencing. *Gene selection by any broadly-relevant set of panels such as PanelApp established for 100,000 Genomes Project interpretations,[46] and is suggested to include categories not related to all phenotypes (as in current study) to control for methodological enrichments. Where TPGI demonstrates evidence of relevance across a patient cohort, this supports attention to a subsequent ‘for personalised genomic interpretations’ (FPGI) stage to be developed within mainstream medicine.

Strengths of the study include WGS of a respectable number of rare disease patients with detailed phenotypic characterisation, spanning a range of severity phenotypes. Unusually for a hospital recruited-population, not all were referred because of personally severe features, with some presenting through family-based screening programmes. Nevertheless, a weakness of the study is that the group did have a bias towards a hospital presentation, and we cannot rule out that the burden of deleterious rare variants would be lower in a community-recruited population, potentially with milder phenotypic spectra. That said, the cohort were not recruited to the 100,000 Genomes Project because of a bleeding, anaemia, thrombotic, or infective phenotype, but instead because they met diagnostic criteria for a separate disease, the endothelial vascular dysplasia HHT. As such they provide an important window on the potential for similar scale, WGS-based high definition analyses in other diseases where phenotypes could be modified by concurrent, otherwise minor diatheses.

All variants identified were rare, at MAFs <0.5%, and therefore do not include two widely distributed polymorphic low expression alleles of *SPTA1*. *Figure 2Bii* indicates that with one exception, there was no reason for variants to segregate with the vasculopathy in families, since almost all variants were widely separated from the HHT genes, usually on different chromosomes. *AK1* is in linkage disequilibrium with *ENG*, and the single *AK1* deleterious variant was identified in an *ENG* family indicating the two are likely to co-segregate in that particular family. However, there was only one variant with a CADD score >15 that was identified in two members of the same family (an *ACVRL1* family). The findings could be extended by incorporating additional genes and categories, and in later individual-level considerations, it may be helpful to distinguish genes associated with dominant phenotypes (such as *ANK1* and *SPTB*) from others in which heterozygous variants are recessive. Further, it is not the place of the current manuscript to explore how these and the wider variants might change HHT clinical practice- such considerations with patient-level integrations are underway through the wider NHS Rare Disease Collaborative Network for HHT and Genomics England Clinical Interpretation Partnership (*Figure 5*). That said, some overview comments are appropriate:

- 11/104 HHT patients were heterozygous for a total of 11 deleterious variants (10 unique variants, 10 different families), in genes where deficiency is known to impact on platelet

function leading to bleeding disorders. Furthermore, these variants were found more commonly in patients defined as having more severe hemorrhage either spontaneously, or precipitated for example by pregnancy, antiplatelet agents, anticoagulants or iron. Currently no attention in HHT management focusses on platelet disorders, yet the current study suggests such considerations alongside modifications to commonly prescribed drugs may be relevant to at least 10% of HHT patients.

- Similarly 13/104 HHT patients were heterozygous for a total of 14 deleterious variants (all unique variants, and in different families), in genes where deficiency is known to impact on the coagulation cascade. The data suggest this may be relevant to more than 12% of HHT patients.
- 24/104 HHT patients were heterozygous for a total of 32 rare deleterious variants (all unique) in genes where deficiency is associated with inherited hemolytic anemias, due to an increased rate of red cell destruction. Again, currently no attention in HHT anemia management focusses on extending the lifespan of endogenous erythrocytes as they suffer additional stresses on passage through HHT vasculature. Cross-over strategies with hemolytic anemias may be relevant to 1 in 4 HHT patients, with particularly attention directed to the subgroup of HHT patients currently receiving intense, intravenous iron regimes on weekly or near-weekly basis.[2,16]

The data suggest that there was no *a priori* reason why the study cohort had their rare, deleterious variants, with the platelet and coagulation deleterious gene variants enriched less compared to GnomAD 3.1, than other categories examined. Instead, comparison with population-level databases predict comparable burdens in other patient populations, drawing attention to new foci for research. For example, while genetic variants predisposing to pathogenic venous thromboses are usually assumed to encode components and mediators of the coagulation cascade, the current cohort suggested a possible trend with erythrocyte enzyme variants, and there has been some discussion of thrombosis in red cell enzymopathy fields.[47] Opportunities to test current associations will be enhanced if enzymopathy genes are included in gene panels for VTE, and further scientific examination appears warranted. Similarly, the observed enrichment of deleterious erythrocyte membrane gene variants in patients

experiencing severe deep-seated infection warrants further study in the setting of the common (daily) bacteremias that can seed abscesses by currently unknown mechanisms.[19,48] Mechanistic examination of whether erythrocyte membrane changes modify macrophage opsonisation rates[49] may influence clinical risk assessments, resulting in extension or restriction of HHT patient cohorts for whom prophylactic antibiotics are recommended.[19-22] Notably, in both study cohort and GnomAD 3.1 populations, the greatest proportion of variants were for the red cell membrane category, where relevance to evolutionary fitness could be postulated.

We conclude that the potential to unmask pathophysiologically-relevant processes is augmented by supplementing binary phenotypic discriminators with severity scales that additionally influence risk-benefit considerations inherent in therapeutic provision. Accelerated pathways to more informed clinical trial design and personalised medical care can be the expected outcome of whole genome sequencing when analytics focus on rare deleterious variants for secondary clinical phenotypes that matter to patients and health care services.

METHODS

Clinical cohort recruitment

Patients attending the Hammersmith Hospital/West London Genomic Medicine Centre for management of HHT were recruited to the 100,000 Genomes Project if the family's HHT pathogenic variant was not already known.[50,51] These comprised patients previously genotyped with no known causal gene identified, and a larger unselected group who had not undergone prior genetic testing and were offered the opportunity to participate during attendance at the clinical service during the recruitment period. Recruitment was offered to all patients attending on those days if they met the clinical diagnosis of HHT [52], and did not have a known genetic cause of HHT. The maximal number of patients was approached, and there was no bias in recruitment to patients with milder or more severe HHT features.

As described for the wider cohort,[7,16,20,53,54] all individuals reviewed in the clinical service were assessed using standardised methods including a detailed clinical history specifically focusing on aspects of the HHT phenotypes, and any disproportionate or unexpected symptomatic manifestations. Standardised hematological and biochemical assessments were performed using the hospital service laboratories as described.[7,16,20,53]

Whole Genome Sequencing

The 100,000 Genomes Project was set up by the UK Department of Health and Social Security in 2013, to sequence whole genomes from National Health Service (NHS) patients recruited through one of 13 Genomic Medicine Centres (GMCs). Patient/family DNA sampling was accompanied by phenotypic data entries and integration with NHS health records. HHT was successfully nominated for inclusion in 2015. During data model set up, human phenotypic ontology (HPO) terms[55] were defined to capture the full range of phenotypes observed in HHT patients, totalling 301 different terms spanning disease manifestations, accessory and incidental phenotypes.[7,55] For each HHT patient recruited between September 2016 and August 2019, relevant HPO terms were submitted to Genomics England following patient recruitment using Open Clinica and Genie.[50]

Genomics England performed all whole genome sequencing (WGS) using the Illumina WGS Service Informatics pipeline for sequence alignments to the National Center for Biotechnology Information Genome Reference Consortium Human (GRCh) build 38/hg38,[39] and variant calling as described.[50] Anonymised outputs from Genomics England internal bioinformatics pipelines and analyses were examined in the Genomics England Research Environment through LabKey.[50]

Candidate modifier gene selection and analysis

Genes were primarily selected based on causal influences on coagulation, hemorrhage, and/or red blood cell (erythrocyte) survival in the general population,[33,34] irrespective of whether a single deleterious allele would be disease-causing (dominant [heterozygous] or X-linked recessive [hemizygous]), or

usually silent (e.g. autosomal recessive, such as thalassaemia or Sickle Cell traits]. The 75 selected genes were categorised by assigning to the single category for their most recognised role across hemoglobin production (i.e. ‘hemoglobinopathy’ genes), red cell (erythrocyte) membrane production (i.e ‘membranopathy’ genes), red cell enzymes (i.e. ‘enzymopathy’ genes); the coagulation cascade, and platelet biology (*Supplementary Table 1*).

Blinded to clinical sub-classifications described below, all DNA sequence variants in patients recruited from West London GMC under the category of HHT were identified in the selected hematological genes (*Supplementary Table 1*). Variant details (number, allele frequencies and CADD scores), and separately, categorised patient numbers, were approved for export through the Research Environment AirLock under subprojects RR42 (HHT-Gene-Stop), and RR43 (Genes, and AVM Development, Physiology, and Compensations in the Pulmonary Circulation (GADP-PAVMs). For export of categorised patient data, identifiers were converted to new codes to prevent inadvertent reveals to the clinical team who generated the phenotypic subcategories- for the purposes of ongoing studies, they remain blinded to patient-level genomic data for the hematological genes.

Gene-level analysis

The burden of usual genetic variation was compared between genes and gene categories by two separate measures. The first used the gene damage index (GDI) which is a genome-wide, gene-level metric of the mutational damage that has accumulated in the general population, and performs well at removing exome variants in genes irrelevant to disease.[31] Genic intolerance was measured by the residual variation intolerance score (RVIS [32]), which performs better for detection of true positives, i.e. genes where newly-identified variants are more likely cause a recognised disease.

Variant-level analysis

To evaluate distributions of affected genes and variants across the genome, the number of genes with variants, and number of variants were examined per Mb of DNA for each chromosome, and Circos[40]

was used on the Galaxy platform[41] to generate a circular ideogram of GRCh38/hg38[36] for visualisations.

To rank likely deleteriousness of identified variants within the study cohort, Combined Annotation Depletion (CADD) scores were extracted from the University of Washington CADD server.[35-37] CADD scores rank the deleteriousness for all 9 billion single nucleotide variants, millions of small indels, and splice site variants based on machine learning trained on diverse genomic features derived from surrounding sequence context, gene model annotations, evolutionary constraint, epigenetic measurements and functional predictions.[35-37] A CADD score greater than 15 is commonly used as a single threshold to indicate likely deleteriousness,[35,42] and performed better than other single measures of deleteriousness using the mutation significance cutoff (MSC) gene-level thresholds for variant-level predictions.[42] With study methodology precluding integration within American College of Medical Genetics-Association for Molecular Pathology clinical care frameworks,[56,57] to enhance predictive power of variant pathogenicity calls, gene-level adjustments were incorporated. For these, we used the MSC 90% and 95% scores which define the 90% and 95% confidence interval lower boundaries of CADD scores of all high quality mutations described in that gene as pathogenic.[42] Generally, variants were categorised as CADD >15 (likely deleterious, incorporating all start loss, stop gain, frameshift, splice donor, splice acceptor, and a small proportion of missense and inframe deletion variants[57]); CADD 5-15 (uncertain significance, comprising most missense and inframe deletions, and some 5' untranslated region and splice region variants); and CADD <5 (likely benign, comprising most synonymous, 5' untranslated region, splice region and intronic variants). The 90% MSC [42] was used to identify genes where variants with lower CADD scores were more likely to be deleterious, and in the final analyses examining deleterious variants against patient phenotypic severity scales, comparisons were made with and without incorporation of gene-specific lower CADD score variants into the deleterious category.

The GnomAD 3.1.1 database, comprising 76,156 genomes and exomes was used as a comparator population.[38] For each of the 75 study genes, we extracted the total number of variants in GnomAD

3.1.1, and likely deleterious variants defined as those flagged as start loss, stop gain, frameshift, splice donor, splice acceptor, loss-of-function, and/or ClinVar-listing as likely pathogenic or pathogenic variants. In view of the differing approaches to classifications (molecular subtype/ClinVar assignments in GnomAD 3.1.1; CADD scores in study cohort), it was not appropriate to compare rates of deleterious variants by genes directly between GnomAD 3.1.1 and the study population. Instead, differential rates were compared between the categories of hematologic genes, enabling less relevant categories to control for methodological sources of enrichment. GnomAD 3.1.1 was also used to define population allele frequencies for the variants identified in the study cohort.

Disease Sub-categorisations

Based on updated clinical information on the recruited patients by 28th April 2021, continuous variables, and severity scales as currently used in our service [7,9,16,53,54] were assigned to all recruited patients, blinded to genotypes beyond the causal HHT variants emerging through clinical diagnostic pipelines:[51]

- HHT-related bleeding was categorised as H0 (as expected for HHT); H1 (precipitated excessive bleeds, i.e. severe bleeds precipitated by a pharmaceutical agent [10,27,28,30], or pregnancy-associated PAVM hemorrhage [14,58]); and H2 (spontaneous excessive bleeds). H2 was assigned for severe daily nosebleeds or gastrointestinal bleeds resulting in hemorrhage adjusted iron requirements (HAIR)[9] exceeding replacement feasibility using oral iron supplementation (resulting in intravenous iron and/or blood transfusion dependency),[16] or for a major spontaneous hemorrhage from a pulmonary[59] or cerebral[15] AVM.
- Anemia was categorised as A0 (within expected range for hemorrhagic losses and iron intake [9,16], and A1 (anemia out-of-proportion to the degree of hemorrhage based on HAIR[9] and the total iron intake from the diet and therapeutic oral or intravenous iron, as detailed in [16]).
- The venous thromboemboli (VTE) categories were T0 (no VTE), T1 (drug, peri-operative or otherwise precipitated VTE/pulmonary embolus), and T2 (spontaneous VTE/pulmonary embolus, using definitions as in [18]).
- Deep-seated infection categories were I0 or I1, with deep seated infection type listed for I1[19-22].

Data Analysis

Summary and comparative statistics were generated using STATA IC v15.0 (Statacorp, College Station, US), STATA IC v16.0 (Statacorp, College Station, US), and GraphPad Prism 9 (GraphPad Software, San Diego, CA). One-way differences between categories were compared by Chi-squared test, and between continuous variables using Kruskal Wallis with Dunn's multiple comparison test to derive p-values for pre-selected pair-wise comparisons. Two-way analyses to incorporate both data source and gene categories were performed using a two-way analysis of variance. The strength and direction of association between ranked variables were examined using Spearman's rank-order correlation. Data were represented using graphics generated in GraphPad Prism 9 (GraphPad Software, San Diego, CA) and STATA IC v 16.0.(Statacorp, College Station, TX).

ACKNOWLEDGEMENTS

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research (NIHR) and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. We thank the National Health Service staff of the UK Genomic Medicine Centre and the families for their willing participation. This research was co-funded by the NIHR Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of funders, the NHS, the NIHR, or the Department of Health and Social Care.

DATA AVAILABILITY STATEMENT

Primary data from the 100,000 Genomes Project, which are held in a secure Research Environment, are available to registered users. Please see <https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access> for further information.

AUTHOR CONTRIBUTIONS

KEJ co-developed the project design; selected gene categories and genes; performed all data analysis within the Genomics England Research Environment and GnomAD 3.1; exported anonymised datasets for numerical interrogation; retrieved all CADD scores; performed quantitative trait association studies, contributed content to Figures 1-4 (1C; 2B-D; 3C; 4B), and contributed to manuscript writing. EO and SB assisted with patient evaluations. FN, KO and KF recruited patients. MS and GT processed patient samples. GT, TF, JR and CLS contributed to project set up at West London Genomic Medicine Centre, and patient recruitment. CMM contributed to coagulation discussions. NC and DML contributed to red cell discussions. MJC set up, and FBP facilitated anonymised analyses within the Genomics England Research environment. GERC performed WGS, sequence alignments and variant calling. CLS set up the HHT-specific projects with Genomics England, the Respiratory Clinical Interpretation Partnership (GeCIP), and at West London GMC, reviewed the patients; categorised phenotypic severities; co-developed the project design; performed remaining data analyses, generated Figures 1-6, and wrote the manuscript. KEJ, CMM, NC, DML and CLS contributed to manuscript revisions. All authors reviewed and approved the final manuscript. CLS is responsible for the overall content as guarantor.

COMPETING INTERESTS STATEMENT

The authors have no competing interests to declare.

REFERENCES

- 1 Precision medicine needs an equity agenda. *Nat Med.* **27**:737 (2021).
- 2 Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. *Ann Intern Med.* **173**(12):989-1001 (2020)
- 3 Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Geisthoff U, Ugolini S, Dupuis-Girod S. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). *Orphanet J Rare Dis.* **13**(1):136. (2018)
- 4 VASCERN HHT 2019a VASCERN-HHT European Reference Network For Vascular Diseases. Hereditary haemorrhagic telangiectasia, available at www.orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&Expert=774 (2019)
- 5 Bideau A, Plauchu H, Brunet G, Robert J. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. *Population* **44**(1):3-22 (1989)
- 6 Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. *J Intern Med.* **245**(1):31-9 (1999)
- 7 Shovlin CL, Simeoni I, Downes K, Frazer ZC, Megy K, Bernabeu-Herrero ME, Shurr A, Brimley J, Patel D, Kell L, Stephens J, Turbin IG, Aldred MA, Penkett CJ, Ouwehand WH, Jovine L, Turro E. Mutational and phenotypic characterisation of hereditary hemorrhagic telangiectasia. *Blood.* **136**(17):1907-1918 (2020)
- 8 Snodgrass RO, Chico TJA, Arthur HM. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions. *Genes (Basel).* **12**(2):174. (2021)
- 9 Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. *PLoS One.* **8**(10):e76516. (2013)
- 10 Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, Suppressa P, Zarrabeitia R, Dupuis-Girod S, Shovlin CL; VASCERN-HHT. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. *Orphanet J Rare Dis.* **14**(1):28. (2019)
- 11 Kjeldsen A, Aagaard KS, Tørring PM, Möller S, Green A. 20-year follow-up study of Danish HHT patients-survival and causes of death. *Orphanet J Rare Dis.* **11**(1):157. (2016)

- 12 de Gussem EM, Edwards CP, Hosman AE, Westermann CJ, Snijder RJ, Faughnan ME, Mager JJ. Life expectancy of parents with Hereditary Haemorrhagic Telangiectasia. *Orphanet J Rare Dis.* **11**:46. (2016)
- 13 Shovlin CL, Hughes JM, Tuddenham EG, Temperley I, Perembelon YF, Scott J, Seidman CE, Seidman JG. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. *Nat Genet.* **6**(2):205-9. (1994)
- 14 Dupuis O, Delagrang L, Dupuis-Girod S. Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature. *Orphanet J Rare Dis.* **15**(1):5. (2020)
- 15 Eker OF, Boccardi E, Sure U, Patel MC, Alicante S, Alsafi A, Coote N, Droege F, Dupuis O, Fialla AD, Jones B, Kariholu U, Kjeldsen AD, Lefroy D, Lenato GM, Mager HJ, Manfredi G, Nielsen TH, Pagella F, Post MC, Rennie C, Sabbà C, Suppressa P, Toerring PM, Ugolini S, Buscarini E, Dupuis-Girod S, Shovlin CL. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). *Orphanet J Rare Dis.* **15**(1):165. (2020)
- 16 Thielemans L, Layton DM, Shovlin CL. Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia. *Haematologica.* **104**(4):e127-e130. (2019)
- 17 Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. *Thromb Haemost.* 2007 Nov;**98**(5):1031-9.
- 18 Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. *Thorax.* **67**(4):328-33. (2012)
- 19 Shovlin C, Bamford K, Sabbà C, Mager HJ, Kjeldsen A, Droege F, Buscarini E, Dupuis-Girod S; VASCERN HHT. Prevention of serious infections in hereditary hemorrhagic telangiectasia: roles for prophylactic antibiotics, the pulmonary capillaries- but not vaccination. *Haematologica.* 2019 **104**(2):e85-e86. (2019)
- 20 Boothe EJ, Brownlow S, Tighe HC, Bamford KB, Jackson JE, Shovlin CL. Cerebral Abscess Associated With Odontogenic Bacteremias, Hypoxemia, and Iron Loading in Immunocompetent Patients With Right-to-Left Shunting Through Pulmonary Arteriovenous Malformations. *Clin Infect Dis.* **65**(4):595-603. (2017)
- 21 Mathis S, Dupuis-Girod S, Plauchu H, et al. Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. *Clin Neurol Neurosurg.* **114**(3): 235-40. (2012)
- 22 Dupuis-Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, Merrot O, Saurin JC, Cordier JF, Plauchu H. Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association. *Clin Infect Dis.* **44**(6):841-5. (2007)
- 23 Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. *Laryngoscope.* **123**(5):1092-9. (2013)

- 24 Finnamore H, Silva BM, Hickson BM, Whelan K, Shovlin CL. 7-day weighed food diaries suggest patients with hereditary hemorrhagic telangiectasia may spontaneously modify their diet to avoid nosebleed precipitants. *Orphanet J Rare Dis.* **12**(1):60. (2017)
- 25 Chamali B, Finnamore H, Manning R, Laffan MA, Hickson M, Whelan K, Shovlin CL. Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study. *Intractable Rare Dis Res.* **5**(2):109-13. (2016)
- 26 Cavalcoli F, Gandini A, Matelloni IA, Catalano F, Alicante S, Manfredi G, Brambilla G, Menozzi F, Perolini F, Costi E, Bertè R, Buscarini E. Dietary iron intake and anemia: food frequency questionnaire in patients with hereditary hemorrhagic telangiectasia. *Orphanet J Rare Dis.* **15**(1):295. (2020)
- 27 Shovlin CL, Gilson C, Busbridge M, Patel D, Shi C, Dina R, Abdulla FN, Awan I. Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia? *Laryngoscope.* **126**(11):2468-2474. (2016)
- 28 Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. *N Engl J Med.* **368**(9):876-8. (2013)
- 29 Gaetani E, Agostini F, Giarretta I, Porfidia A, Di Martino L, Gasbarrini A, Pola R, On Behalf Of The Multidisciplinary Gemelli Hospital Group For Hht. Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry. *J Clin Med.* **9**(6):1699. (2020)
- 30 Shovlin CL, Millar CM, Droege F, Kjeldsen A, Manfredi G, Suppressa P, Ugolini S, Coote N, Fialla AD, Geisthoff U, Lenato GM, Mager HJ, Pagella F, Post MC, Sabbà C, Sure U, Torring PM, Dupuis-Girod S, Buscarini E; VASCERN-HHT. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. *Orphanet J Rare Dis.* **14**(1):210. (2019)
- 31 Itan Y, Shang L, Boisson B, Patin E, Bolze A, Moncada-Vélez M, Scott E, Ciancanelli MJ, Lafaille FG, Markle JG, Martinez-Barricarte R, de Jong SJ, Kong XF, Nitschke P, Belkadi A, Bustamante J, Puel A, Boisson-Dupuis S, Stenson PD, Gleeson JG, Cooper DN, Quintana-Murci L, Claverie JM, Zhang SY, Abel L, Casanova JL. The human gene damage index as a gene-level approach to prioritizing exome variants. *Proc Natl Acad Sci U S A.* **112**(44):13615-20. (2015)
- 32 Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes. *PLOS Genetics.* **9**(8):e1003709. (2013)
- 33 Kim Y, Park J, Kim M. Diagnostic approaches for inherited hemolytic anemia in the genetic era. *Blood Res.* **52**(2): 84-94. (2017)
- 34 Downes K, Megy K, Duarte D, Vries M, Gebhart J, Hofer S, Shamardina O, Deevi SVV, Stephens J, Mapeta R, Tuna S, Al Hasso N, Besser MW, Cooper N, Daugherty L, Gleadall N, Greene D, Haimel M, Martin H, Papadia S, Revel-Vilk S, Sivapalaratnam S, Symington E, Thomas W, Thys C, Tolios A, Penkett CJ; NIHR BioResource, Ouwehand WH, Abbs S, Laffan MA, Turro E, Simeoni I, Mumford AD, Henskens YMC, Pabinger

- I, Gomez K, Freson K.. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. *Blood*. **134**(23): 2082–2091. (2019)
- 35 Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. **46**(3):310-5. (2014)
- 36 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res*. **47**(D1):D886-D894. (2019)
- 37 Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. *Genome Med*. **13**(1):31. (2021)
- 38 Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O’Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME; Genome Aggregation Database Consortium, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. **581**(7809):434-443. doi: 10.1038/s41586-020-2308-7. (2020)
- 39 National Center for Biotechnology Information Genome Reference Consortium Human Build 38/hg38, available at https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/
- 40 Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA. Circos: an information aesthetic for comparative genomics. *Genome Res*. **19**(9):1639-45. (2009)
- 41 Jalili V, Afgan E, Gu Q, Clements D, Blankenberg D, Goecks J, Taylor J, Nekrutenko A. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2020 update. *Nucleic Acids Res*. **48**(W1):W395-W402. (2020)
- 42 Itan Y, Shang L, Boisson B, Ciancanelli MJ, Markle JG, Martinez-Barricarte R, Scott E, Shah I, Stenson PD, Gleeson J, Cooper DN, Quintana-Murci L, Zhang SY, Abel L, Casanova JL. The mutation significance cutoff: gene-level thresholds for variant predictions. *Nat Methods*. **13**(2):109-10. (2016)
- 43 Epi25 Collaborative. Epi25 Collaborative. Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. *Am J Hum Genet*. **108**(6):965-982. (2021)
- 44 Keramati AR, Chen MH, Rodriguez BAT, Yanek LR, Bhan A, Gaynor BJ, Ryan K, Brody JA, Zhong X, Wei Q; NHLBI Trans-Omics for Precision (TOPMed) Consortium, Kammers K, Kanchan K, Iyer K, Kowalski MH, Pitsillides AN, Cupples LA, Li B, Schlaeger TM, Shuldiner AR, O’Connell JR, Ruczinski I, Mitchell BD,

Faraday N, Taub MA, Becker LC, Lewis JP, Mathias RA, Johnson AD. Genome sequencing unveils a regulatory landscape of platelet reactivity. *Nat Commun.* **12**:3626. (2021)

45 Hu Y, Stilp AM, McHugh CP, Rao S, Jain D, Zheng X, Lane J, Méric de Bellefon S, Raffield LM, Chen MH, Yanek LR, Wheeler M, Yao Y, Ren C, Broome J, Moon JY, de Vries PS, Hobbs BD, Sun Q, Surendran P, Brody JA, Blackwell TW, Choquet H, Ryan K, Duggirala R, Heard-Costa N, Wang Z, Chami N, Preuss MH, Min N, Ekunwe L, Lange LA, Cushman M, Faraday N, Curran JE, Almasy L, Kundu K, Smith AV, Gabriel S, Rotter JI, Fornage M, Lloyd-Jones DM, Vasan RS, Smith NL, North KE, Boerwinkle E, Becker LC, Lewis JP, Abecasis GR, Hou L, O'Connell JR, Morrison AC, Beaty TH, Kaplan R, Correa A, Blangero J, Jorgenson E, Psaty BM, Kooperberg C, Walton RT, Kleinstiver BP, Tang H, Loos RJF, Soranzo N, Butterworth AS, Nickerson D, Rich SS, Mitchell BD, Johnson AD, Auer PL, Li Y, Mathias RA, Lettre G, Pankratz N, Laurie CC, Laurie CA, Bauer DE, Conomos MP, Reiner AP; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program. *Am J Hum Genet.* **108**:874-893. (2021)

46 Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, Leong IUS, Smith KR, Gerasimenko O, Haraldsdottir E, Thomas E, Scott RH, Baple E, Tucci A, Brittain H, de Burca A, Ibañez K, Kasperaviciute D, Smedley D, Caulfield M, Rendon A, McDonagh EM. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet.* **51**(11):1560-1565. (2019)

47 Zaninoni A, Fermo E, Vercellati C, Marcello AP, Barcellini W, Bianchi P. Congenital Hemolytic Anemias: Is There a Role for the Immune System? *Front Immunol.* **11**:1309. (2020)

48 Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J, Medina Henríquez J, Lockhart PB, Chu VH, Diz Dios P. Intravenous amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. *J Antimicrob Chemother.* **71**:2022-2030. (2016)

49 Kanoi BN, Nagaoka H, White MT, Morita M, Palacpac NMQ, Ntege EH, Balikagala B, Yeka A, Egwang TG, Horii T, Tsuboi T, Takashima E. Global Repertoire of Human Antibodies Against Plasmodium falciparum RIFINs, SURFINs, and STEVORs in a Malaria Exposed Population. *Front Immunol.* **11**:893. (2020)

50 Genomics England Confluence. *Research Environment User Guide - Genomics England Research Environment*. Available at:

<https://research-help.genomicsengland.co.uk/display/GERE/Research+Environment+User+Guide> (2021)

51 Clarke JM, Alikian M, Xiao S, Kasperaviciute D, Thomas E, Turbin I, Olupona K, Cifra E, Curetean E, Ferguson T, Redhead J; Genomics England Research Consortium, Shovlin CL. Low grade mosaicism in hereditary haemorrhagic telangiectasia identified by bidirectional whole genome sequencing reads through the 100,000 Genomes Project clinical diagnostic pipeline. *J Med Genet.* **57**(12):859-862. (2020)

- 52 Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). *Am J Med Genet.* **91**(1):66-7. (2000)
- 53 Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, Manning R, Laffan MA, Meek J, Tighe HC, Jackson JE. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. *PLoS One.* **9**(2):e88812. (2014)
- 54 Gawecki F, Strangeways T, Amin A, Perks J, McKernan H, Thurainatnam S, Rizvi A, Jackson JE, Santhirapala V, Myers J, Brown J, Howard LS, Tighe HC, Shovlin CL. Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations. *QJM.* **112**(5):335-342.(2019)
- 55 Köhler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I, Black GC, Brown DL, Brudno M, Campbell J, FitzPatrick DR, Eppig JT, Jackson AP, Freson K, Girdea M, Helbig I, Hurst JA, Jähn J, Jackson LG, Kelly AM, Ledbetter DH, Mansour S, Martin CL, Moss C, Mumford A, Ouwehand WH, Park SM, Riggs ER, Scott RH, Sisodiya S, Van Vooren S, Wapner RJ, Wilkie AO, Wright CF, Vulto-van Silfhout AT, de Leeuw N, de Vries BB, Washington NL, Smith CL, Westerfield M, Schofield P, Ruef BJ, Gkoutos GV, Haendel M, Smedley D, Lewis SE, Robinson PN. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. *Nucleic Acids Res* **42** (Database issue):D966-74 (2014)
- 56 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* **17**(5):405-24. (2015)
- 57 Davieson CD, Joyce KE, Sharma L, Shovlin CL. DNA variant classification –reconsidering ‘allele rarity’ and ‘phenotype’ criteria in ACMG/AMP guidelines. *Eur J Med Genet.* Aug 16:104312. doi: 10.1016/j.ejmg.2021.104312. Online ahead of print. (2021).
- 58 Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE, Sheppard MN. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. *BJOG.* **115**(9):1108-15. (2008)
- 59 Shovlin CL, Condliffe R, Donaldson JW, Kiely DG, Wort SJ; British Thoracic Society. British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations. *Thorax.* **72**(12):1154-1163. (2017)

DATA SUPPLEMENT

Supplementary Table 1

The 75 selected hematological genes by category

HGNC Symbol	Gene name	General population relevant phenotype (s)	GnomAD deleterious	Any variant	Total variants	CADD >15 variants
Haemoglobin production						
ATRX	ATRX chromatin remodeller	Alpha-thalassemia myelodysplasia syndrome	75	1	1	0
CDAN1	Codanin 1	Dyserythropoietic anemia, TYPE Ia;	19	1	2	1
HBA1	Hemoglobin alpha	Alpha thalassemia	29	0		
HBA2	H Hemoglobin alpha emoglobin alpha		51	0		
HBB	Hemoglobin beta	Beta thalassemia	315	0		
HBG2	Hemoglobin gamma	Fetal hemoglobin quantitative trait	6	1	1	0
HbS1L	HbS1-like translational GTPase	Beta thalassemia /Sickle cell disease/other	0	1	1	1
HBZ	Hemoglobin subunit zeta (embryonic)	Alpha thalassemia	0	1	2	2
KIF23	Kinesin family member 23	Dyserythropoietic Anemia, type III	1	1	1	1
KLF1	Kruppel-like factor 1	Dyserythropoietic Anemia, type IV	15	0		
SEC23B	SC 23 homologue B	Dyserythropoietic Anemia, type II	22	0		
Erythrocyte membrane production						
ANK1	Ankyrin	Hereditary spherocytosis type 1	37	1	2	2
EPB41	Erythrocyte Membrane Protein Band 4.1	Hereditary elliptocytosis	6	1	4	3
EPB41L1	Erythrocyte Membrane Protein Band 4.1 Like 1	Not yet defined	2	1	3	0
EPB41L2	Erythrocyte Membrane Protein Band 4 1 Like 2	Hereditary elliptocytosis	0	1	1	1
EPB41L3	Erythrocyte Membrane Protein Band 4.1 Like 3	Not yet defined	0	1	3	0
EPB41L4A	Erythrocyte Membrane Protein Band 4.1 like 4A	Not yet defined	1	0		
EPB41L4B	Erythrocyte Membrane Protein Band 4.1 like 4B	Giant hemangioma	0	1	2	1
EPB41L5	Erythrocyte Membrane Protein Band 4.1 Like 5	Not yet defined	0	1	1	1
EPB42	Erythrocyte Membrane Protein Band 42	Hereditary spherocytosis type 5	8	0		
KCNN4	Potassium channel, calcium-activated, intermediate/small conductance, subfamily N, member 4	Dehydrated hereditary stomatocytosis 2	4	1	2	0
PIEZO1	Piezo-type mechanosensitive ion channel component 1	Dehydrated hereditary stomatocytosis	38	1	24	3
SLC4A1	Solute carrier family 4 (anion exchanger), member 1;	Hereditary spherocytosis type 4	47	0		
SLC4A1AP	solute carrier family 4 adaptor protein	-	0	1	2	0
SPTA1	Erythrocytic alpha spectrin	Hereditary elliptocytosis-2, pyropoikilocytosis, & spherocytosis, type 3	49	1	6	3

<i>SPTB</i>	Erythrocytic beta spectrin	Hereditary spherocytosis type 2	27	1	6	5
<i>Erythrocyte enzymopathies</i>						
<i>AK1</i>	Adenylate kinase 1	Nonspherocytic hemolytic anemia	7	1	1	1
<i>BPGM</i>	Bisphosphoglycerate Mutase	Hemolytic anemia	5	1	1	1
<i>ENO1</i>	Enolase 1	Not yet defined	0	0		
<i>G6PD</i>	glucose-6-phosphate dehydrogenase	Acute hemolysis; severe chronic non-spherocytic hemolytic anemia	44	1	1	0
<i>GCLC</i>	Glutamate-Cysteine Ligase Catalytic Subunit	Hemolytic anemia	2	0		
<i>GPI</i>	Glucose-6-Phosphate Isomerase	Nonspherocytic hemolytic anemia	11	1	1	1
<i>GPX1</i>	Glutathione Peroxidase 1	Hemolytic anemia	0	1	1	1
<i>GSR</i>	Glutathione-Disulfide Reductase	Hemolytic anemia	2	0		
<i>GSS</i>	Glutathione synthetase	Hemolytic anemia	10	1	2	1
<i>HK1</i>	Hexokinase 1	Hemolytic anemia	9	1	1	1
<i>NT5C3A</i>	Pyrimidine 5-prime-nucleotidase	Hemolytic anemia	11	0		
<i>PGK1</i>	Phosphoglycerate kinase 1	Hemolytic anemia	16	1	1	1
<i>PKLR</i>	Pyruvate Kinase	Chronic hereditary nonspherocytic hemolytic anemia	24	0		
<i>TPI1</i>	Triosephosphate Isomerase 1	Hemolytic anemia	9	1	1	1
<i>Coagulation</i>						
<i>F2</i>	Thrombin (coagulation factor II)	Prothrombin deficiency/ thrombosis and dysprothrombinemia	17	0		
<i>F2R</i>	Coagulation Factor II Thrombin Receptor	Thrombosis	0	1	1	0
<i>F2RL1</i>	Coagulation Factor II Thrombin Receptor-like 1	Not yet defined	0	0		
<i>F2RL2</i>	Coagulation Factor II Thrombin Receptor-like 2	Think you need to include	11	0		
<i>F2RL3</i>	Coagulation Factor II Thrombin Receptor-like 3	Not yet defined	0	1	1	1
<i>F3</i>	Tissue factor (coagulation factor III)	Disseminated Intravascular Coagulation (COVID and HIV roles)	0	0		
<i>F5</i>	Coagulation factor V	Autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance.	28	1	2	2
<i>F7</i>	Coagulation factor VII	Factor VII deficiency	31	1	1	1
<i>F8</i>	Coagulation factor VIII	Hemophilia A	338	1	3	1
<i>F9</i>	Coagulation factor IX	Hemophilia B	157	0		
<i>F10</i>	Coagulation factor X	Factor X deficiency	12	0		

<i>F11</i>	Coagulation factor XI	Factor XI deficiency	91	1	3	3
<i>F12</i>	Coagulation factor XII	Hereditary angioedema type III	6	0		
<i>F13A1</i>	Coagulation factor XIII A chain	Factor XIIIa deficiency	23	1	1	1
<i>F13B</i>	Coagulation factor XIII B chain	Factor XIIIb deficiency	6	1	1	1
<i>PROC</i>	Protein C, Inactivator of coagulation factors Va And VIIIa	Protein C deficiency (prothrombotic)	58	0		
<i>PROS1</i>	Protein S	Protein S deficiency (prothrombotic)	43	1	1	0
<i>SERPINC1</i>	Antithrombin-III	Antithrombin-III deficiency which constitutes a strong risk factor for thrombosis.	58	0		
<i>VWF</i>	Von Willebrand Factor	von Willebrand disease	233	1	4	4
Platelets						
<i>ACTN1</i>	Actinin Alpha 1	Bleeding Disorder, Platelet-Type, 15	24	0		
<i>ANKRD26</i>	Ankyrin Repeat Domain 26	Autosomal dominant thrombocytopenia-2	1	1	1	1
<i>DIAPH1</i>	Diaphanous Related Formin 1	Thrombocytopenia (with deafness)	22	1	1	1
<i>ETV6</i>	ETS Variant Transcription Factor 6	Bleeding Disorder, Platelet-Type	13	0		
<i>GNE</i>	Glucosamine (UDP-N-Acetyl)-2-Epimerase/N-Acetylmannosamine Kinase	Thrombocytopenia (with myopathy)	91	1	2	2
<i>GP1BA</i>	Glycoprotein Ib platelet alpha subunit	Platelet-type von Willebrand disease; Macrothrombocytopenia	23	1	2	1
<i>GP1BB</i>	Glycoprotein Ib platelet beta subunit	Macrothrombocytopenia	16	0		
<i>HPS1</i>	HPS1, biogenesis of lysosomal organelles complex 1	Hermansky-Pudlak syndrome	55	1	1	1
<i>HPS6</i>	HPS6, biogenesis of lysosomal organelles complex 2 subunit 3	Hermansky-Pudlak syndrome	27	0		
<i>ITGA2B</i>	Platelet Glycoprotein IIb/Integrin Subunit Alpha 2b	Platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation	99	1	1	1
<i>ITGB3</i>	Platelet Glycoprotein IIIa/Integrin Subunit Beta 3	Bleeding Disorder, Platelet-Type, 16	70	0		
<i>MYH9</i>	Myosin Heavy Chain 9	Macrothrombocytopenia	39	1	1	1
<i>RASGRP2</i>	RAS Guanyl Releasing Protein 2	Bleeding disorder, platelet-type, 18	13	1	2	1
<i>RUNX1</i>	Runt-related transcription factor 1	Platelet disorder, familial, with associated myeloid malignancy	77	0		
<i>TBXA2R</i>	Thromboxane A2 receptor	Bleeding disorder, platelet-type, 13		1	1	1
<i>TUBB1</i>	Beta tubulin	Macrothrombocytopenia	12	1	1	1

Genomics England Research Consortium

The Genomics England Research Consortium

John C. Ambrose¹; Prabhu Arumugam¹; Roel Bevers¹; Marta Bleda¹ ; Freya Boardman-Pretty^{1,2} ; Christopher R. Boustred¹; Helen Brittain¹ ; Mark J. Caulfield^{1,2}; Georgia C. Chan¹; Greg Elgar^{1,2} ; Tom Fowler¹ ; Adam Giess¹ ; Angela Hamblin¹; Shirley Henderson^{1,2}; Tim J. P. Hubbard¹ ; Rob Jackson¹ ; Louise J. Jones^{1,2}; Dalia Kasperaviciute^{1,2}; Melis Kayikci¹ ; Athanasios Kousathanas¹ ; Lea Lahnstein¹; Sarah E. A. Leigh¹ ; Ivonne U. S. Leong¹ ; Javier F. Lopez¹; Fiona Maleady-Crowe¹; Meriel McEntagart¹ ; Federico Minneci¹; Loukas Moutsianas^{1,2} ; Michael Mueller^{1,2} ; Nirupa Murugaesu¹; Anna C. Need^{1,2} ; Peter O'Donovan¹ ; Chris A. Odhams¹ ; Christine Patch^{1,2} ; Mariana Buongiorno Pereira¹ ; Daniel Perez-Gil¹; John Pullinger¹ ; Tahrima Rahim¹ ; Augusto Rendon¹ ; Tim Rogers¹; Kevin Savage¹; Kushmita Sawant¹; Richard H. Scott¹; Afshan Siddiq¹ ; Alexander Sieghart¹ ; Samuel C. Smith¹ ; Alona Sosinsky^{1,2} ; Alexander Stuckey¹ ; Mélanie Tanguy¹ ; Ana Lisa Taylor Tavares¹; Ellen R. A. Thomas^{1,2} ; Simon R. Thompson¹ ; Arianna Tucci^{1,2} ; Matthew J. Welland¹; Eleanor Williams¹ ; Katarzyna Witkowska^{1,2}; Suzanne M. Wood^{1,2}.

1. Genomics England, London, UK

2. William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK.